Viridian Therapeutics, Inc.
VRDNNASDAQHealthcare● Active
$15.73
$-0.05(-0.32%)
Market Cap$1.4B
P/E Ratio—
52W High$34.29
52W Low$13.18
Viridian Therapeutics, Inc. (VRDN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VRDN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $70.85M | $0.30M | $0.31M | $1.77M | $2.96M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $70.85M | $0.30M | $0.31M | $1.77M | $2.96M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $338.93M | $238.25M | $159.76M | $100.89M | $56.89M |
| G&A Expenses | $95.31M | $61.08M | $95.00M | $35.18M | $25.80M |
| Total Operating Expenses | $434.24M | $299.34M | $254.76M | $136.08M | $82.69M |
| Operating Income | ($363.39M) | ($299.04M) | ($254.45M) | ($134.30M) | ($79.73M) |
| Operating Margin %(computed) | -512.91% | — | — | — | — |
| Interest Income | $27.40M | $32.13M | $18.56M | $4.92M | $0.32M |
| Interest Expense | $4.95M | $3.05M | $1.85M | $0.49M | $0.00M |
| Income Before Tax | ($342.60M) | ($269.95M) | ($237.73M) | ($129.87M) | ($79.41M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($342.60M) | ($269.95M) | ($237.73M) | ($129.87M) | ($79.41M) |
| Net Margin %(computed) | -483.57% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.32 | $-3.98 | $-5.31 | $-3.91 | $-6.66 |
| Wtd Avg Shares | 84.80M | 67.89M | 44.76M | 32.09M | 11.92M |
| EBITDA | ($337.19M) | ($265.66M) | ($235.37M) | ($129.13M) | ($79.29M) |
| EBITDA Margin %(computed) | -475.93% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Viridian Therapeutics, Inc. data
About Viridian Therapeutics, Inc. (VRDN) Income Statement
Viridian Therapeutics, Inc. (VRDN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, VRDN reported revenue of $0.07B, gross profit of $0.07B (gross margin 100.00%), and net income of ($0.34B) — a net profit margin of -483.57%.
Frequently asked questions
VRDN · 4 questionsViridian Therapeutics, Inc. (VRDN) reported revenue of $0.07B for 2025, up 23359.9% year-over-year.
VRDN revenueVRDN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08